[A21-133] Atezolizumab (NSCLC; first line) - Addendum to Commission A21-69
Last updated 19.11.2021
Project no.:
A21-133
Commission:
Commission awarded on 12.10.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
First-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression in ≥ 50% of the tumour cells (TC) and who do not have EGFR mutations or ALK-positive NSCLC
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-69 | Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021-11-19 A G-BA decision was published.